Is the minimum inhibitory concentration of vancomycin an infallible predictor of the clinical outcome of staphylococcus aureus bacteremia treated with vancomycin?

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 642-643

  Pea, Federico ^a,b   Viale, Pierluigi ^b  

^a Institute of Clinical Pharmacology and Toxicology   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OXACILLIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; LETTER; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SPAIN; STAPHYLOCOCCUS AUREUS; UNIVERSITY HOSPITAL; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; HUMANS; MICROBIAL SENSITIVITY TESTS; SPAIN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 67651100436     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603589     Document Type: Letter

References (10)

1. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-re- sistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
2. Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997-8.
3. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006;42: 1764-71.
4. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66:82-98.
5. Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006; 12:92-5.
6. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of path- ophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44:1009-34.
7. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-7.
8. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study. Antimicrob Agents Chemother 2009; 53:1863-7.
9. Roberts JA, Lipman J, Blot S, Rello J. Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care 2008; 14:390-6.
10. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staph- ylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.